Belgian Banks Stock News

UCB (ENXTBR:UCB) has put BIMZELX center stage at the 2026 American Academy of Dermatology meeting, releasing three year and four year data across hidradenitis suppurativa and plaque psoriasis that emphasizes durable clinical responses. See our latest analysis for UCB. UCB's recent dermatology data drop comes after a strong run in the shares, with a year to date share price return of 14.35% and a very large 5 year total shareholder return of 251.93%. This suggests momentum has been building...

As European markets experience a boost in sentiment due to hopes of a shorter Middle East conflict, indices like the STOXX Europe 600 and Germany's DAX have shown notable gains. In this environment, identifying stocks that may be trading below their estimated value can offer opportunities for investors looking to capitalize on potential market inefficiencies.

Sofina Société Anonyme (ENXTBR:SOF) reported full year 2025 earnings with net income of €113 million, down sharply from €1,359.51 million a year earlier, a shift that is front of mind for shareholders. See our latest analysis for Sofina Société Anonyme. The latest full year results appear to have weighed on sentiment, with Sofina Société Anonyme posting a 30 day share price return decline of 9.63% and a 90 day share price return decline of 14.86%, while the 1 year total shareholder return...

Umicore shares react to muted near term performance Umicore (ENXTBR:UMI) is back in focus after a period where the stock has seen mixed returns, with weakness over the past 3 months and year to date, contrasting with a strong 1 year total return. See our latest analysis for Umicore. At a share price of €16.35, Umicore’s recent 90 day share price return of 16.75% and year to date share price return of 12.05% sit alongside a very strong 1 year total shareholder return of 116.88%. However, the 3...

Soft earnings didn't appear to concern Van de Velde NV's ( EBR:VAN ) shareholders over the last week. Our analysis...

Without a specific news event triggering the move, Fluxys Belgium (ENXTBR:FLUX) is drawing attention as investors reassess its recent share performance and the underlying gas transmission, storage, and LNG terminalling business. See our latest analysis for Fluxys Belgium. Despite a 1-day share price decline of 2.79% to €20.9 and some recent short-term weakness, the 90-day share price return of 9.42% and 1-year total shareholder return of 6.84% point to momentum that contrasts with weaker 3-...

Ackermans & Van Haaren (ENXTBR:ACKB) has just wrapped up FY 2025 with second half revenue of €2.9b, basic EPS of €9.78 and trailing twelve month EPS of €18.14. This frames a year where earnings growth of 28.9% ran ahead of the five year EPS pace of 7.7% per year. Over the last twelve months, revenue has been described as growing at about 2.8% per year while the trailing net margin moved from 7.6% to 9.9%, so the latest half sits against a backdrop of firmer profitability. For investors, that...

Onward Medical (ENXTBR:ONWD) has reported its FY 2025 first half with revenue of €1.2 million, a basic EPS loss of €0.47, and net income loss of €21.2 million, setting a clear tone for another year focused on growth over profitability. The company has seen revenue move from €0.2 million in the first half of 2024 to €1.5 million in the second half of 2024 and €1.2 million in the first half of 2025. Basic EPS has shifted between losses of €0.53, €0.32, and €0.47 over the same periods,...

Syensqo (ENXTBR:SYENS) has wrapped up FY 2025 with fourth quarter revenue of €1,384 million and basic EPS of a €1.61 loss, while the trailing twelve months show revenue of €5,969 million and basic EPS of a €0.85 loss. Over recent quarters, revenue has moved from €1,662 million in Q4 2024 to €1,678 million in Q1 2025, €1,639 million in Q2 2025, €1,558 million in Q3 2025, and €1,384 million in Q4 2025, with EPS swinging between a €1.28 loss and a €0.49 gain before landing at a €1.61 loss this...

Recent share performance context Anheuser-Busch InBev (ENXTBR:ABI) has seen mixed recent returns, with the stock up 1.7% over the past day and 1.6% over the past week, while showing a 9.7% decline over the past month. See our latest analysis for Anheuser-Busch InBev. At a share price of €60.74, Anheuser-Busch InBev has a positive year to date share price return of 11.65%, while the 1 year total shareholder return of 7.5% suggests momentum has cooled after a stronger recent quarter. If you are...

As European markets navigate the complexities of Middle East conflicts and energy price volatility, indices like the STOXX Europe 600 have shown modest gains, reflecting a cautious optimism amidst geopolitical uncertainties. In these fluctuating times, dividend stocks can offer investors a measure of stability and potential income, making them an appealing consideration for those looking to balance risk with consistent returns.

Syensqo share performance snapshot Syensqo (ENXTBR:SYENS) has attracted attention after a recent move that left the stock about 2% higher over the past month, yet showing a roughly 28% decline over the past 3 months. Over the past year, Syensqo’s total return is about 20% lower, while year to date performance shows a similar decline of around 29%. These moves provide context for assessing its current valuation. See our latest analysis for Syensqo. Syensqo’s share price, now at €49.48, has...

Syensqo has redeemed €500 million of senior bonds that were originally due in 2027. This move completes a wider debt refinancing step following the company’s recent spin off. The early redemption changes the company’s debt profile and may influence future interest costs. The bond redemption comes at a time when Syensqo (ENXTBR:SYENS) shares trade around €49.0. The stock has seen a 12.6% gain over the past week, while returns over the past month, year to date, and past year show declines of...

Anheuser-Busch InBev (ENXTBR:ABI) has announced the upcoming retirement of Board Chairman Martin J. Barrington after nearly a decade of board service. Barrington, who remained in his role beyond the customary retirement age at the board's request, is set to step down following multiple extended terms. His departure represents a planned transition in the top tier of the brewer's governance structure. Anheuser-Busch InBev, the global brewer behind some of the world's largest beer brands,...

SCR-Sibelco N.V.'s ( EBR:094426466 ) healthy profit numbers didn't contain any surprises for investors. However the...

Sofina Société Anonyme (ENXTBR:SOF) opened FY 2025 with a weak first half, reporting a loss as basic EPS swung to €11.87 and total revenue came in at a loss of €358.9 million. This comes against a backdrop where the trailing twelve months still show positive EPS of €12.48 and revenue of €486.1 million. Over the past year, the company has seen total revenue move from €587.1 million in 2024 H1 to €844.98 million in 2024 H2 and EPS shift from €16.59 to €24.29 in the same periods, before the...

The European market has recently faced challenges, with the pan-European STOXX Europe 600 Index declining by 3.79% amid heightened geopolitical tensions and soaring energy costs, prompting caution from the European Central Bank regarding inflation risks. In this environment of uncertainty, high-growth tech stocks in Europe are gaining attention for their potential to offer resilience and innovation-driven growth, making them an intriguing focus for investors seeking opportunities in a...

Today is shaping up negative for Banqup Group SA ( EBR:BANQ ) shareholders, with the analysts delivering a substantial...

SCR-Sibelco (ENXTBR:094426466) has put fresh numbers on the table for FY 2025, reporting first half revenue of €1.2b and net income of €78.1m, while trailing 12 month revenue is €2.3b against net income of €63.4m. Over the past year, revenue has moved from €1.1b in the first half of 2024 and €1.1b in the second half of 2024 to €1.2b in the first half of 2025. Net income shifted from €145.9m to a loss of €14.7m and then to €78.1m over the same periods. For investors, the key storyline is how...

Nyxoah (ENXTBR:NYXH) just wrapped up FY 2025 with Q4 revenue of €5.6 million and a basic EPS loss of €0.586, alongside trailing twelve month revenue of €10.0 million and a basic EPS loss of €2.364 on net income losses of €90.1 million. Over recent quarters the company has seen revenue move from €1.3 million in Q4 2024 to €5.6 million in Q4 2025, while quarterly basic EPS losses widened from €0.463 to €0.586 and trailing twelve month net income losses went from €59.2 million to €90.1 million...

argenx (ENXTBR:ARGX) is back in focus after strong fourth quarter results and detailed analyst commentary around Vyvgart, with attention now shifting to the product’s revenue mix and upcoming clinical catalysts. See our latest analysis for argenx. Despite strong Q4 Vyvgart revenues and upcoming data presentations at the AAN meeting drawing attention to the pipeline, argenx’s recent 30 day share price return of 14.04% decline and year to date share price return of 17.13% decline contrast with...

For those wondering if Anheuser-Busch InBev at around €63.44 still offers value or if most of the upside is already priced in, this article walks through the key numbers so you can judge that for yourself. The share price has seen mixed recent returns, with about 0.2% over the last 7 days, a 6.3% decline over 30 days, 16.6% year to date, and 10.9% over the past year. This raises questions about how much of the story is already reflected in the current price. Recent headlines around...

What Elia Group’s latest earnings mean for shareholders Elia Group (ENXTBR:ELI) released full year 2025 results on 5 March, reporting sales of €4,442.2m and net income of €585.9m, figures that helped shape recent sentiment around the stock. See our latest analysis for Elia Group. Elia Group’s recent earnings update has arrived alongside firm share price momentum, with a 28.6% 90 day share price return and a 70.54% 1 year total shareholder return indicating that optimism has been building...

D'Ieteren Group (ENXTBR:DIE) has just posted its FY 2025 numbers with first half revenue of about €4.1b and basic EPS of €4.61, backed by trailing 12 month EPS of €8.40 that lines up with reported earnings growth of 17.3% over the past year. The company has seen revenue move from about €4.3b in the first half of 2024 and €3.9b in the second half of 2024 to €4.1b in the first half of 2025. Trailing 12 month net income, excluding extra items, sits at €445m, alongside earnings growth of roughly...